BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 21928244)

  • 1. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
    Wang Q; Zhang W; Li DR; Li L
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 4. [Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspension array technology].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li DR; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Oct; 51(10):765-772. PubMed ID: 27788745
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.
    Zohny SF; Fayed ST
    Med Oncol; 2010 Dec; 27(4):1246-53. PubMed ID: 19937162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
    Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
    J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.
    Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE
    Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
    Tempfer C; Hefler L; Heinzl H; Loesch A; Gitsch G; Rumpold H; Kainz C
    Br J Cancer; 1998 Oct; 78(8):1108-12. PubMed ID: 9792159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying serum biomarkers for ovarian cancer by screening with surface-enhanced laser desorption/ionization mass spectrometry and the artificial neural network.
    Yang J; Zhu Y; Guo H; Wang X; Gao R; Zhang L; Zhao Y; Zhang X
    Int J Gynecol Cancer; 2013 May; 23(4):667-72. PubMed ID: 23574802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
    Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
    Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    van Breemen MJ; Bleijlevens B; de Koster CG; Aerts JM
    Biochim Biophys Acta; 2006 Oct; 1764(10):1626-32. PubMed ID: 17010683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
    Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.